Amarin Corp Plc (AMRN) Posts Q4 Loss of 26c/Share; Update on Ops
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Aegis Capital Keeps Amarin (AMRN) at 'Hold'; Cautious on Vascepa for Dyslipidemia Strategy
February 28, 2014 9:22 AM ESTAegis Capital reaffirms its Hold rating and $2 price target on Amarin Coop plc (Nasdaq: AMRN) on Friday following Q4 results and update.
Analyst Ram Selvaraju commented, We believe that Amarin can achieve management's stated financial goals, even with a significantly reduced revenue base for Vascepa in hypertriglyceridemia only. However, we remain... More
Amarin (AMRN) Sues FDA; Seeks Five Year Vascepa Exclusivity
February 27, 2014 5:07 PM ESTAmarin Corp plc (Nasdaq: AMRN) has sued the U.S. FDA over exclusivity for fish oil pill, according to Bloomberg headlines. The company said the FDA unfairly changed rules for market exclusivity and that its Vascepa is entitled to five years of exclusivity. The suit was filed in Washington.... More
